Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy

We appreciate our colleagues' interest in our recent article entitled ‘Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy’, in which we reported the validation of the prognostic and predictive ability of a drug-based score in patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab [ [1] Buti S. Bersanelli M. Perrone F. et al....